Rekah Pharmaceutical (Israel) Performance
| REKA Stock | ILA 1,422 16.00 1.11% |
The company holds a Beta of -0.33, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Rekah Pharmaceutical are expected to decrease at a much lower rate. During the bear market, Rekah Pharmaceutical is likely to outperform the market. Rekah Pharmaceutical right now holds a risk of 3.37%. Please check Rekah Pharmaceutical maximum drawdown, potential upside, and the relationship between the treynor ratio and value at risk , to decide if Rekah Pharmaceutical will be following its historical price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Rekah Pharmaceutical Industry has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Rekah Pharmaceutical is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 36.9 M | |
| Total Cashflows From Investing Activities | -35.9 M |
Rekah |
Rekah Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 145,000 in Rekah Pharmaceutical Industry on August 29, 2024 and sell it today you would lose (2,800) from holding Rekah Pharmaceutical Industry or give up 1.93% of portfolio value over 90 days. Rekah Pharmaceutical Industry is generating 0.0135% of daily returns and assumes 3.3676% volatility on return distribution over the 90 days horizon. Simply put, 29% of stocks are less volatile than Rekah, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Rekah Pharmaceutical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rekah Pharmaceutical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Rekah Pharmaceutical Industry, and traders can use it to determine the average amount a Rekah Pharmaceutical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.004
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | REKA |
Estimated Market Risk
| 3.37 actual daily | 30 70% of assets are more volatile |
Expected Return
| 0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Rekah Pharmaceutical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Rekah Pharmaceutical by adding Rekah Pharmaceutical to a well-diversified portfolio.
Rekah Pharmaceutical Fundamentals Growth
Rekah Stock prices reflect investors' perceptions of the future prospects and financial health of Rekah Pharmaceutical, and Rekah Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Rekah Stock performance.
| Return On Equity | 0.0222 | |||
| Return On Asset | 0.0208 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.05 % | |||
| Current Valuation | 316.92 M | |||
| Shares Outstanding | 11.41 M | |||
| Price To Book | 1.11 X | |||
| Price To Sales | 0.63 X | |||
| Revenue | 263.95 M | |||
| EBITDA | 36.2 M | |||
| Cash And Equivalents | 31.61 M | |||
| Cash Per Share | 2.77 X | |||
| Total Debt | 101.23 M | |||
| Debt To Equity | 1.01 % | |||
| Book Value Per Share | 14.39 X | |||
| Cash Flow From Operations | 21.17 M | |||
| Earnings Per Share | 0.32 X | |||
| Total Asset | 437.09 M | |||
| Retained Earnings | 49 M | |||
| Current Asset | 246 M | |||
| Current Liabilities | 90 M | |||
About Rekah Pharmaceutical Performance
By analyzing Rekah Pharmaceutical's fundamental ratios, stakeholders can gain valuable insights into Rekah Pharmaceutical's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Rekah Pharmaceutical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Rekah Pharmaceutical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company was founded in 1941 and is based in Holon, Israel. REKAH PHARMA operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 9 people.Things to note about Rekah Pharmaceutical performance evaluation
Checking the ongoing alerts about Rekah Pharmaceutical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Rekah Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Rekah Pharmaceutical had very high historical volatility over the last 90 days | |
| About 37.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Rekah Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Rekah Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining Rekah Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Rekah Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Rekah Pharmaceutical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Rekah Pharmaceutical's stock. These opinions can provide insight into Rekah Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Rekah Stock analysis
When running Rekah Pharmaceutical's price analysis, check to measure Rekah Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rekah Pharmaceutical is operating at the current time. Most of Rekah Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Rekah Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rekah Pharmaceutical's price. Additionally, you may evaluate how the addition of Rekah Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |